Herpes labialis treatment with acyclovir 5 per cent ointment

J Can Dent Assoc. 1989 Feb;55(2):135-7.


Eighty patients who were culture-confirmed positive for recurrent herpes labialis were entered into a clinical trial. Sixty of these completed two episodes each in a randomized, double-blind, placebo-controlled clinical trial of 5 per cent acyclovir in a polyethylene glycol ointment base. The 5 per cent acyclovir ointment failed to show better clinical healing effects than placebo in both documented episodes. There were no serious side effects observed in either group.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / administration & dosage
  • Acyclovir / therapeutic use*
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Herpes Labialis / drug therapy*
  • Humans
  • Male
  • Ointments
  • Placebos
  • Polyethylene Glycols
  • Random Allocation
  • Recurrence


  • Ointments
  • Placebos
  • Polyethylene Glycols
  • Acyclovir